← 返回

CD19/CD22 双靶向 CAR-T 细胞疗法桥接异基因造血干细胞移植治疗 B 细胞急性淋巴细胞白血病延迟血小板恢复并增加移植后巨细胞病毒和 EB 病毒血症风险

英文原题:CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and Epstein-Barr virus viremia after transplantation.

查看英文原题

CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and Epstein-Barr virus viremia after transplantation.

PubMed 2023/10/01(内容时间) Clin Transl Med Q1 · IF 7.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

摘要

这条来源本身就没有摘要(PubMed 未提供),不是「还没翻译」。可以点最下面的「在 PubMed 查看」打开原文献页面。

论文信息

作者
Li S、Ge J、Zhou S、Zhu W、Han Y、Chen S、Xue S、Wang Y
单位
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.China
文献类型
读者来信 · 非美国政府资助研究
期刊
Clinical and translational medicine2023 Oct
原文标识
PubMed 37882317 · DOI 10.1002/ctm2.1459